I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Nigel Crockett Biography and Net Worth

Insider of Bicycle Therapeutics

Nigel Crockett, Ph.D., is chief business officer of Bicycle Therapeutics.

Nigel joined Bicycle Therapeutics from Tukan Partners Ltd., which he founded as a consultancy providing hands-on, transactional, commercial expertise for a broad range of biotech clientsfrom around the world. Prior to founding Tukan Partners, Nigel was a member of the management team at Astex, completing 14 deals for the company. Previously, Nigel held commercial and senior management roles at several pharma-biotech companies, including Heptares (now Sosei-Heptares), Microbiotica, Crescendo Biologics, NodThera, Clinical Designs Ltd. and Cantab Pharmaceuticals. In more than 25 years, he built expertise in the licensing of early- and late-stage clinical assets and company financing and has completed more than 50 major deals, establishing industry-leading strategic collaborations in a multitude of key therapeutic areas.He previously chaired the U.K.’s BioIndustry Association, Business Development Working Group.

Nigel received his B.S. in chemistry from the University of Manchester and obtained a Ph.D. in Molecular Biology from Cambridge University.

What is Nigel Crockett's net worth?: The estimated net worth of Nigel Crockett is at least $715,150.88 as of January 3rd, 2024. Dr. Crockett owns 48,716 shares of Bicycle Therapeutics stock worth more than $715,151 as of December 21st. This net worth evaluation does not reflect any other investments that Dr. Crockett may own. Learn More about Nigel Crockett's net worth.
How do I contact Nigel Crockett?: The corporate mailing address for Dr. Crockett and other Bicycle Therapeutics executives is B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT. Bicycle Therapeutics can also be reached via phone at 441223261503 and via email at [email protected]. Learn More on Nigel Crockett's contact information.
Has Nigel Crockett been buying or selling shares of Bicycle Therapeutics?: Nigel Crockett has not been actively trading shares of Bicycle Therapeutics over the course of the past ninety days. Most recently, Nigel Crockett sold 2,643 shares of the business's stock in a transaction on Wednesday, January 3rd. The shares were sold at an average price of $17.50, for a transaction totalling $46,252.50. Following the completion of the sale, the insider now directly owns 48,716 shares of the company's stock, valued at $852,530. Learn More on Nigel Crockett's trading history.
Who are Bicycle Therapeutics' active insiders?: Bicycle Therapeutics' insider roster includes Stephen Alexander (SVP), Kate Bingham (Director), Nigel Crockett (Insider), Lee Kalowski (CFO), Nicholas Keen (Insider), Kevin Lee (CEO), and Pierre Legault (Director). Learn More on Bicycle Therapeutics' active insiders.
Are insiders buying or selling shares of Bicycle Therapeutics?: In the last twelve months, Bicycle Therapeutics insiders bought shares 2 times. They purchased a total of 1,485,397 shares worth more than $21,229,062.72. In the last twelve months, insiders at the sold shares 17 times. They sold a total of 32,657 shares worth more than $683,852.68. The most recent insider tranaction occured on December, 16th when Director Bros. Advisors Lp Baker bought 500,000 shares worth more than $7,670,000.00. Insiders at Bicycle Therapeutics own 8.5% of the company. Learn More about insider trades at Bicycle Therapeutics.
Information on this page was last updated on 12/16/2024.

Nigel Crockett Insider Trading History at Bicycle Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/3/2024	Sell	2,643	$17.50	$46,252.50	48,716
1/3/2023	Sell	1,801	$29.06	$52,337.06	30,699
7/13/2021	Sell	72,701	$32.44	$2,358,420.44	4,331
7/6/2021	Sell	271	$32.00	$8,672.00	271

Nigel Crockett Buying and Selling Activity at Bicycle Therapeutics

Bicycle Therapeutics Company Overview

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Today's Range

Now: $14.68

$14.64

$15.30

50 Day Range

MA: $21.83

$13.81

$27.51

2 Week Range

Now: $14.68

$12.17

$28.67

Volume

346,432 shs

Average Volume

404,265 shs

Market Capitalization

$1.01 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.86

I was wrong. Dead wrong.

From Porter & Company | Ad